Want to see XNCR full AI Analyst Report?
XNCR Stock Chart & Stats
$19.44
$0.42(2.16%)
At close: 4:00 PM EDT
$19.44
$0.42(2.16%)
Day’s Range― - ―
52-Week Range$6.92 - $21.76
Previous Close$19.86
Volume942.30K
Average Volume (3M)1.04M
Market Cap
$1.50B
Enterprise Value$637.69
Total Cash (Recent Filing)$444.95M
Total Debt (Recent Filing)$175.16M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.29
Shares Outstanding74,141,594
10 Day Avg. Volume1,146,628
30 Day Avg. Volume1,035,385
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.79
Price to Sales (P/S)9.05
P/FCF Ratio-8.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.13Price Target Upside29.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.83
Revenue Forecast (FY)$76.73M
Bulls Say, Bears Say
Bulls Say
Settlement Boosts Near-term Cash RunwayThe $105M settlement converts uncertain U.S. royalty receipts into near-term, non-dilutive cash received in two installments and management says it restores operating runway through 2028. This materially reduces near-term financing pressure and supports funding of planned clinical milestones and R&D execution over the multi-year horizon.
Low Leverage Provides Balance-sheet FlexibilityRelatively low debt and a reduced debt-to-equity ratio give the company flexibility to fund ongoing R&D via cash, partnerships, or selective financing without onerous interest burdens. For a clinical-stage biotech this lowers refinancing risk and helps preserve strategic optionality while clinical programs de-risk over the next 2–3 years.
Proprietary XmAb Platform And TL1A PipelineXencor's antibody-engineering platform (XmAb, Xtend Fc) and advancing TL1A autoimmune/IBD candidates create durable competitive advantages. Platform-derived molecules and multiple upcoming clinical readouts through 2026–2027 support the potential for differentiated, longer-acting biologics and provide multiple value-inflection points if clinical data validate superiority in a multibillion-dollar IBD market.
Bears Say
High Cash BurnSustained, large negative operating and free cash flows indicate the company is consuming cash materially to fund R&D and operations. Continued burn elevates financing risk, potentially forcing dilutive equity raises or onerous deals if clinical progress stalls, and means runway improvements (like the settlement) are critical but not a permanent fix absent durable cash generation.
Declining Revenue With Deep Net LossesA meaningful decline in TTM revenue paired with very large negative net margins shows the business has not yet translated R&D into scalable product revenues. Persistent operating losses pressure returns, reduce reinvestment capacity, and make long-term viability dependent on successful clinical outcomes, milestone timing, or additional financing.
Loss Of Future U.S. Ultomiris Royalties Reduces Recurring RevenueTrading future U.S. royalties for a lump-sum settlement reduces predictable, long-term royalty cash flow. While ex-U.S. royalties remain, the elimination of the U.S. stream lessens future recurring revenue diversification and increases reliance on the pipeline and partnerships to generate sustainable, repeatable revenue beyond the near-term cash benefit.
Xencor News
XNCR FAQ
What was Xencor Inc.’s price range in the past 12 months?
Xencor Inc. lowest stock price was $6.92 and its highest was $21.76 in the past 12 months.
What is Xencor Inc.’s market cap?
Xencor Inc.’s market cap is $1.50B.
When is Xencor Inc.’s upcoming earnings report date?
Xencor Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 96 days.
How were Xencor Inc.’s earnings last quarter?
Xencor Inc. released its earnings results on Aug 05, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.801 by $0.511.
Is Xencor Inc. overvalued?
According to Wall Street analysts Xencor Inc.’s price is currently Undervalued.
Does Xencor Inc. pay dividends?
Xencor Inc. does not currently pay dividends.
What is Xencor Inc.’s EPS estimate?
Xencor Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xencor Inc. have?
Xencor Inc. has 74,141,594 shares outstanding.
What happened to Xencor Inc.’s price movement after its last earnings report?
Xencor Inc. reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.801. Following the earnings report the stock price went down -5.38%.
Which hedge fund is a major shareholder of Xencor Inc.?
Currently, no hedge funds are holding shares in XNCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.13 (29.24% Upside)
$25.13 (29.24% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.55%
Trailing 12-Months
Company Description
Xencor Inc.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XNCR Stock 12 Month Forecast
Average Price Target
$25.13
▲(29.24% Upside)
Technical Analysis
CytomX Therapeutics
―
AnaptysBio
―
Zymeworks
―
AbCellera Biologics
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.55% Insiders
29.38% Mutual Funds
1.06% Other Institutional Investors
43.01% Public Companies and
Individual Investors